0001209191-23-010734.txt : 20230217 0001209191-23-010734.hdr.sgml : 20230217 20230217170128 ACCESSION NUMBER: 0001209191-23-010734 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230215 FILED AS OF DATE: 20230217 DATE AS OF CHANGE: 20230217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gallagher Patrick Stephen CENTRAL INDEX KEY: 0001932215 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39980 FILM NUMBER: 23643675 MAIL ADDRESS: STREET 1: 66 HAROLD ST CITY: BOSTON STATE: MA ZIP: 02119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001829802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 620 PROFESSIONAL DRIVE CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: (240) 243-8000 MAIL ADDRESS: STREET 1: 620 PROFESSIONAL DRIVE CITY: GAITHERSBURG STATE: MD ZIP: 20879 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-15 0 0001829802 Sensei Biotherapeutics, Inc. SNSE 0001932215 Gallagher Patrick Stephen C/O SENSEI BIOTHERAPEUTICS, INC. 451 D STREET, SUITE 710 BOSTON MA 02210 0 1 0 0 Chief Business Officer Common Stock 2023-02-15 4 A 0 29313 0.00 A 29313 D Common Stock 2023-02-15 4 A 0 14200 0.00 A 43515 D Stock Option (Right to Buy) 1.43 2023-02-15 4 A 0 60000 0.00 A 2023-02-14 Common Stock 60000 60000 D These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested. These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date. The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. /s/ Mark Ballantyne, Attorney-in-Fact 2023-02-17